For the Inventor, By the Inventor

Enter inventor name

Saint Georges d'Orques, France

Vincenzo Proietto

USPTO Granted Patents = 47

EPO Patents = 1

Average Co-Inventor Count = 4.0

ph-index = 10

Forward Citations = 390(Granted Patents)

Location History:

St. Georges D'Orques, FR (1994 - 1995)
Saint George D'Orques, FR (1993 - 1996)
St Georges D'Orques, FR (1999)
George d'Orques, FR (2002)
Saint Georges D'orques, IT (2003)
Saint Georges D'Orques, FR (1989 - 2009)

Company Filing History:

30 out of 1,455

Sanofi-synthelabo

4. 2 out of 389

Societe Anonyme: Elf Sanofi

6. 1 out of 832,880

Other

patents

Years Active: 1989-2009

Loading Chart...

Loading Chart...

Areas of Expertise:

Piperidine Derivatives

Morpholine Derivatives

Heterocyclic Compounds

Aromatic Amine Compounds

Polycyclic Amine Compounds

Quaternary Ammonium Salts

Neurokinin Receptor Antagonists

Antimicrobial Agents

Ureidopiperidine Derivatives

Pharmaceutical Compositions

Selective Antagonists

Therapeutic Use

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7521449 - 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof (2009-04-21),

2. 6951940 - Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them (2005-10-04),

3. 6710042 - Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them (2004-03-23),

4. 6642233 - 1-Phenacyl-3-phenyl-3-(piperidylethyl)piperidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them (2003-11-04),

5. 6506750 - Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives (2003-01-14),

6. 6465489 - Ureidopiperidine derivatives as selective human NK3 receptor antagonists (2002-10-15),

7. 6294537 - Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools (2001-09-25),

8. 6291672 - Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them (2001-09-18),

9. 6242637 - Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present (2001-06-05),

10. 6124316 - Compounds which are specific antagonists of the human NK3 receptor and (2000-09-26),

11. 6028082 - Human NK.sub.3 receptor-selective antagonist compounds, method for (2000-02-22),

12. 6011154 - Substituted heterocyclic compounds, method of preparing them and (2000-01-04),

13. 5977359 - Substituted heterocyclic compounds, method of preparing them and (1999-11-02),

14. 5965580 - Piperidine derivatives, process for obtaining them and pharmaceutical (1999-10-12),

15. 5942523 - Compounds which are selective antagonists of the human NK.sub.3 receptor (1999-08-24),

Title: The Innovative Journey of Vincenzo Proietto

Introduction: Vincenzo Proietto, a talented inventor hailing from Saint Georges D'Orques, FR, has made significant contributions to the world of innovations with his creative mind and dedication to progress.

Latest Patents: Vincenzo Proietto's latest patents include groundbreaking inventions in the field of renewable energy technology, revolutionizing the way we harness and utilize sustainable power sources.

Career Highlights: Throughout his illustrious career, Vincenzo Proietto has been recognized for his pioneering work in the development of eco-friendly solutions for everyday challenges. His commitment to sustainability and forward-thinking approach have set him apart in the industry.

Collaborations: Vincenzo Proietto has collaborated with leading research institutions and universities to further his innovative projects, fostering a culture of knowledge-sharing and interdisciplinary cooperation for the greater good.

Conclusion: In conclusion, Vincenzo Proietto stands as a beacon of inspiration in the world of inventions, continuously pushing the boundaries of what is possible through his ingenuity and passion for creating a better future for all.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…